Boston Biotech Hub Purchase Starts to Pay off for AstraZeneca
Back in 2021, AstraZeneca bought Alexion Pharma in a $39 billion deal that was something of a landmark in the industry. It was thought that this acquisition would trigger all kinds of antitrust issues, especially in the light of a threatened renewal in antitrust scrutiny, and yet the deal sailed through in April last year. Now, all of the blood, sweat and tears that must have gone into making that deal happen have all proven to be worth it as...
View full press release